Document is current
Any future updates will be listed below
-
Authors
Briot, Karine https://orcid.org/0000-0002-6238-2601
Portale, Anthony A
Brandi, Maria Luisa
Carpenter, Thomas O
Cheong, Hae Ii
Cohen-Solal, Martine https://orcid.org/0000-0002-8582-8258
Crowley, Rachel K
Eastell, Richard
Imanishi, Yasuo
Ing, Steven
Insogna, Karl
Ito, Nobuaki
Jan de Beur, Suzanne
Javaid, Muhammad K
Kamenicky, Peter
Keen, Richard
Kubota, Takuo
Lachmann, Robin H
Perwad, Farzana
Pitukcheewanont, Pisit
Ralston, Stuart H
Takeuchi, Yasuhiro
Tanaka, Hiroyuki
Weber, Thomas J
Yoo, Han-Wook
Nixon, Annabel
Nixon, Mark
Sun, Wei
Williams, Angela
Imel, Erik A https://orcid.org/0000-0002-7284-3467
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02526160 at ClinicalTrials.govnct02526160 at ClinicalTrials.govDocuments that mention this clinical trial
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
https://doi.org/10.1136/rmdopen-2021-001714
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
nct02526160 at ClinicalTrials.govDocuments that mention this clinical trial
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
https://doi.org/10.1136/rmdopen-2021-001714
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
Documents that mention this clinical trial
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
https://doi.org/10.1136/rmdopen-2021-001714
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
-
Funding
Funding for this research was provided by:
Kyowa Kirin International (N/A)
- License Information
